



## Cardiovascular 2016-2017

### MEASURE-BY-MEASURE

**0066**                      **Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy - Diabetes or Left Ventricular Systolic Dysfunction (LVEF & 40%)**

\_\_\_\_\_ I approve the measure for NQF Endorsement  
\_\_\_\_\_ I disapprove the measure for NQF Endorsement  
\_\_\_\_\_ I abstain from voting on this measure

**0076**                      **Optimal Vascular Care**

\_\_\_\_\_ I approve the measure for NQF Endorsement  
\_\_\_\_\_ I disapprove the measure for NQF Endorsement  
\_\_\_\_\_ I abstain from voting on this measure

**0290**                      **Median Time to Transfer to Another Facility for Acute Coronary Intervention**

\_\_\_\_\_ I approve the measure for NQF Endorsement  
\_\_\_\_\_ I disapprove the measure for NQF Endorsement  
\_\_\_\_\_ I abstain from voting on this measure

**2906**                      **Coronary Artery Disease (CAD): Beta-Blocker Therapy-Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF & 40%)**

\_\_\_\_\_ I approve the measure for NQF Endorsement  
\_\_\_\_\_ I disapprove the measure for NQF Endorsement  
\_\_\_\_\_ I abstain from voting on this measure